Kinesis Pharma BV (Kinesis) and the Medicines for Children Research Network (MCRN) jointly enter the market of developing and evaluating medicines to be used in children. Both parties have extensive experience in the field of development and evaluation of medicines in paediatric use; Kinesis from the industrial and regulatory angle, the MCRN from the clinical approach.
The first phase of the collaboration will be the definition of the joint activities, which will primarily focus on providing services in the development and evaluation phase of paediatric drugs.
The joint efforts of Kinesis and MCRN should lead to a better and faster development of drugs to be used in children. As the expertises and experiences of Kinesis and MCRN are fully complimentary, both parties anticipate they can offer a strong platform to pharmaceutical and biotech industry to efficiently develop and evaluate their products.
The combination of Kinesis and MCRN will not only focus on the clinical evaluation, but can also facilitate in other segments of medicines evaluation, such as studies in juvenile non-clinical models, optimisation of formulations (e.g. tablets, capsules, solutions, etc.), and regulatory processes.
About Kinesis
Kinesis is an independent, privately owned, drug development consultancy company with the mission to facilitate a fast and high quality drug development process in close collaboration with the chemical-pharmaceutical, preclinical and clinical R&D departments of pharmaceutical and biotech companies through consultancy and contract research services. Kinesis staff (about 55) is highly experienced with strong background in the pharmaceutical and biotech industry, and regulatory authorities.
Kinesis Pharma BV, Lage Mosten 29, 4822 NK Breda,
tel.: + 31 76 548 0666, fax + 31 76 542 1777, www.kinesis-pharma.com
|
